Suggested reading
Gralla R, Lichinitser M, Van Der Vegt S, et al: Palonosetron(Drug information on palonosetron) improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron(Drug information on ondansetron). Ann Oncol 14:1570–1577, 2003.
Grunberg S, Chua D, Maru A, et al: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin(Drug information on cisplatin) therapy: Randomized, double-blind study protocol - EASE. J Clin Oncol 29:1495-1501, 2011.
Kris MG, Gralla RJ, Clark RA, et al: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384, 1985.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098, 2003.
Rojas C, Stathis M, Thomas AG, et al: Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478, 2008.
Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone(Drug information on dexamethasone) versus granisetron(Drug information on granisetron) plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124, 2009.
Tremblay PB, Kaiser R, Sezer O, et al: Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21:2147–2155, 2003.
Abbreviations in this chapter
ASCO = American Society of Clinical Oncology; MASCC = Multinational Association of Supportive Care in Cancer
